Literature DB >> 12607086

[Modern imaging modalities in renal disease: CT and MRI].

P Rogalla1, M Taupitz, B Hamm.   

Abstract

Considerable technical advances have been made in computed tomography (CT) and magnetic resonance imaging (MRI) over the last 10 years. Both modalities allow for high-resolution imaging of the entire abdomen before as well as during the arterial and parenchymal perfusion phase after intravenous contrast medium administration. Multiplanar reconstructions of the three-dimensional source data sets yield views in any spatial orientation. Maximum intensity projections enable the generation of CT or MR angiographies as well as CT or MR urographies from delayed images. Thus, both modalities today allow for comprehensive diagnostic evaluation of renal disease by a single examination comprising detailed visualization of the parenchyma as well as of arterial and venous vessels and assessment of excretion. CT and MRI thus enable efficient preoperative diagnostic assessment in particular in patients with renal masses.

Entities:  

Mesh:

Year:  2003        PMID: 12607086     DOI: 10.1007/s00120-002-0293-0

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  10 in total

Review 1.  Different phases of renal enhancement: role in detecting and characterizing renal masses during helical CT.

Authors:  B I Yuh; R H Cohan
Journal:  AJR Am J Roentgenol       Date:  1999-09       Impact factor: 3.959

Review 2.  [Organ-sparing surgery of renal cell carcinoma - operative technique and findings in radiological follow-up].

Authors:  P Hallscheidt; J Hansmann; J P Schenk; B A Radeleff; G W Kauffmann; G Riedasch
Journal:  Rofo       Date:  2002-04

Review 3.  [Contrast media for magnetic resonance tomographic lymph node diagnosis (MR lymphography)].

Authors:  M Taupitz; S Wagner; B Hamm
Journal:  Radiologe       Date:  1996-02       Impact factor: 0.635

Review 4.  From the archives of the AFIP. Infiltrative renal lesions: radiologic-pathologic correlation. Armed Forces Institute of Pathology.

Authors:  P J Pickhardt; G J Lonergan; C J Davis; N Kashitani; B J Wagner
Journal:  Radiographics       Date:  2000 Jan-Feb       Impact factor: 5.333

5.  Ipsilateral adrenal involvement from renal cell carcinoma: retrospective study of the predictive value of computed tomography.

Authors:  Yuka Sawai; Toshiaki Kinouchi; Masayuki Mano; Norio Meguro; Osamu Maeda; Masao Kuroda; Michiyuki Usami
Journal:  Urology       Date:  2002-01       Impact factor: 2.649

Review 6.  Three-dimensional gadolinium-enhanced MR angiography: applications for abdominal imaging.

Authors:  J F Glockner
Journal:  Radiographics       Date:  2001 Mar-Apr       Impact factor: 5.333

7.  Clinical and pathologic tumor size in renal cell carcinoma; difference, correlation, and analysis of the influencing factors.

Authors:  Ozgur Yaycioglu; Matthew P Rutman; Mamtha Balasubramaniam; Kenneth M Peters; Jose A Gonzalez
Journal:  Urology       Date:  2002-07       Impact factor: 2.649

8.  Staging of 119 patients with renal cell carcinoma: the yield and cost-effectiveness of pelvic CT.

Authors:  J R Fielding; N Aliabadi; A A Renshaw; S G Silverman
Journal:  AJR Am J Roentgenol       Date:  1999-01       Impact factor: 3.959

9.  Multidetector CT: detection of active hemorrhage in patients with blunt abdominal trauma.

Authors:  Jürgen K Willmann; Justus E Roos; Andreas Platz; Thomas Pfammatter; Paul R Hilfiker; Borut Marincek; Dominik Weishaupt
Journal:  AJR Am J Roentgenol       Date:  2002-08       Impact factor: 3.959

10.  Enlargement of regional lymph nodes in renal cell carcinoma is often not due to metastases.

Authors:  U E Studer; S Scherz; J Scheidegger; R Kraft; R Sonntag; D Ackermann; E J Zingg
Journal:  J Urol       Date:  1990-08       Impact factor: 7.450

  10 in total
  1 in total

Review 1.  [New techniques in computed tomography. Significance for urology].

Authors:  J Stattaus; M Forsting; M Goyen
Journal:  Urologe A       Date:  2004-11       Impact factor: 0.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.